Cargando…
Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis
OBJECTIVE: Patients with anti‐melanoma‐differentiation‐associated 5 (anti‐MDA5)‐positive dermatomyositis (DM) share several striking similarities to patients with SARS‐CoV‐2. Our objective was to assess the prevalence of anti‐angiotensin converting enzyme‐2 (ACE2) immunoglobulin M (IgM) antibodies,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096520/ https://www.ncbi.nlm.nih.gov/pubmed/35229496 http://dx.doi.org/10.1002/acr2.11423 |
_version_ | 1784705994024026112 |
---|---|
author | Mecoli, Christopher A. Yoshida, Akira Paik, Julie J. Lin, Cheng Ting Danoff, Sonye Hanaoka, Hironari Rosen, Antony Christopher‐Stine, Lisa Kuwana, Masataka Casciola‐Rosen, Livia |
author_facet | Mecoli, Christopher A. Yoshida, Akira Paik, Julie J. Lin, Cheng Ting Danoff, Sonye Hanaoka, Hironari Rosen, Antony Christopher‐Stine, Lisa Kuwana, Masataka Casciola‐Rosen, Livia |
author_sort | Mecoli, Christopher A. |
collection | PubMed |
description | OBJECTIVE: Patients with anti‐melanoma‐differentiation‐associated 5 (anti‐MDA5)‐positive dermatomyositis (DM) share several striking similarities to patients with SARS‐CoV‐2. Our objective was to assess the prevalence of anti‐angiotensin converting enzyme‐2 (ACE2) immunoglobulin M (IgM) antibodies, found in patients with severe SARS‐CoV‐2, in two independent anti‐MDA5‐positive DM cohorts. METHODS: Anti‐ACE2 IgM antibodies were assayed by enzyme‐linked immunosorbent assay (ELISA) in two anti‐MDA5‐positive DM cohorts: a predominantly outpatient North American cohort (n = 52) and a Japanese cohort enriched for new‐onset disease (n = 32). Additionally, 118 patients with SARS‐CoV‐2 with a spectrum of clinical severity were tested for anti‐MDA5 antibodies by ELISA. RESULTS: Five of fifty‐two (9.6%) North American patients and five of thirty‐two (15%) Japanese patients were positive for anti‐ACE2 IgM. In the North American cohort, all five patients with anti‐ACE2 IgM antibodies had proximal muscle weakness, had interstitial lung disease, were significantly more likely to receive pulse dose methylprednisolone (80% vs 30%, P = 0.043), and had worse forced vital capacity (median 59% predicted vs 78%, P = 0.056) compared with the anti‐ACE2‐IgM‐negative group. In the Japanese cohort, all five anti‐ACE2‐IgM‐positive patients also required pulse dose methylprednisolone, and three of five (60%) patients died. Japanese patients with anti‐ACE2 IgM had significantly worse oxygenation, as defined by a lower partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio (233 vs 390, P = 0.021), and a higher alveolar‐arterial oxygenation gradient (91 vs 23 mm Hg, P = 0.024) than the IgM‐negative group. CONCLUSION: We describe anti‐ACE2 IgM autoantibodies in two independent cohorts with anti‐MDA5‐positive DM. These autoantibodies may be biomarkers for severe disease and provide insight into disease pathogenesis. |
format | Online Article Text |
id | pubmed-9096520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wiley Periodicals, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90965202022-05-18 Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis Mecoli, Christopher A. Yoshida, Akira Paik, Julie J. Lin, Cheng Ting Danoff, Sonye Hanaoka, Hironari Rosen, Antony Christopher‐Stine, Lisa Kuwana, Masataka Casciola‐Rosen, Livia ACR Open Rheumatol Brief Report OBJECTIVE: Patients with anti‐melanoma‐differentiation‐associated 5 (anti‐MDA5)‐positive dermatomyositis (DM) share several striking similarities to patients with SARS‐CoV‐2. Our objective was to assess the prevalence of anti‐angiotensin converting enzyme‐2 (ACE2) immunoglobulin M (IgM) antibodies, found in patients with severe SARS‐CoV‐2, in two independent anti‐MDA5‐positive DM cohorts. METHODS: Anti‐ACE2 IgM antibodies were assayed by enzyme‐linked immunosorbent assay (ELISA) in two anti‐MDA5‐positive DM cohorts: a predominantly outpatient North American cohort (n = 52) and a Japanese cohort enriched for new‐onset disease (n = 32). Additionally, 118 patients with SARS‐CoV‐2 with a spectrum of clinical severity were tested for anti‐MDA5 antibodies by ELISA. RESULTS: Five of fifty‐two (9.6%) North American patients and five of thirty‐two (15%) Japanese patients were positive for anti‐ACE2 IgM. In the North American cohort, all five patients with anti‐ACE2 IgM antibodies had proximal muscle weakness, had interstitial lung disease, were significantly more likely to receive pulse dose methylprednisolone (80% vs 30%, P = 0.043), and had worse forced vital capacity (median 59% predicted vs 78%, P = 0.056) compared with the anti‐ACE2‐IgM‐negative group. In the Japanese cohort, all five anti‐ACE2‐IgM‐positive patients also required pulse dose methylprednisolone, and three of five (60%) patients died. Japanese patients with anti‐ACE2 IgM had significantly worse oxygenation, as defined by a lower partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio (233 vs 390, P = 0.021), and a higher alveolar‐arterial oxygenation gradient (91 vs 23 mm Hg, P = 0.024) than the IgM‐negative group. CONCLUSION: We describe anti‐ACE2 IgM autoantibodies in two independent cohorts with anti‐MDA5‐positive DM. These autoantibodies may be biomarkers for severe disease and provide insight into disease pathogenesis. Wiley Periodicals, Inc. 2022-03-01 /pmc/articles/PMC9096520/ /pubmed/35229496 http://dx.doi.org/10.1002/acr2.11423 Text en © 2022 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Report Mecoli, Christopher A. Yoshida, Akira Paik, Julie J. Lin, Cheng Ting Danoff, Sonye Hanaoka, Hironari Rosen, Antony Christopher‐Stine, Lisa Kuwana, Masataka Casciola‐Rosen, Livia Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis |
title | Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis |
title_full | Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis |
title_fullStr | Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis |
title_full_unstemmed | Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis |
title_short | Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis |
title_sort | presence and implications of anti‐angiotensin converting enzyme‐2 immunoglobulin m antibodies in anti‐melanoma‐differentiation‐associated 5 dermatomyositis |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096520/ https://www.ncbi.nlm.nih.gov/pubmed/35229496 http://dx.doi.org/10.1002/acr2.11423 |
work_keys_str_mv | AT mecolichristophera presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis AT yoshidaakira presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis AT paikjuliej presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis AT linchengting presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis AT danoffsonye presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis AT hanaokahironari presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis AT rosenantony presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis AT christopherstinelisa presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis AT kuwanamasataka presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis AT casciolarosenlivia presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis |